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OBJECTIVES The purpose of this study was to determine whether higher left ventricular inotropic reserve,
defined as the increase in left ventricular ejection fraction (LVEF) in response to intravenous
dobutamine infusion, or other ventriculographic variables predict the increase in LVEF after
beta-blocker therapy in patients with nonischemic cardiomyopathy (NICM).
BACKGROUND Long-term beta-blocker therapy increases LVEF in some patients with NICM. Other than
dose, there are no definite predictors of LVEF increase.
METHODS Thirty patients with LVEF #0.35 and NICM underwent assessment of LVEF at rest and
after a 10-min intravenous infusion of dobutamine at 10 mg/kg/min, using equilibrium
radionuclide ventriculography. Age was 49 6 11 years, 33% women, functional class 2.6 6
0.5, duration of chronic heart failure 3.2 6 2.9 years, LVEF 0.21 6 0.07, left ventricular
end-diastolic volume index 180 6 64 ml/m2. Right ventricular ejection fraction (RVEF) was
abnormal in 37%. Mean dobutamine-induced augmentation of LVEF (DoDLVEF) was
0.12 6 0.08. Patients were started on one of three beta-blockers (carvedilol, bucindolol or
metoprolol) and the dose was advanced to the maximum tolerated.
RESULTS Left ventricular ejection fraction, reassessed 7.4 6 5.9 months after maximum beta-blocker
dose was reached, increased to 0.34 6 0.13 (p 5 0.0006). The following baseline variables
correlated with improvement of LVEF: DoDLVEF (p 5 0.001), RVEF (p 5 0.005), systolic
blood pressure at end of dobutamine infusion (p 5 0.02) and dose of beta-blocker (p 5 0.07).
In a multivariate analysis, only DoDLVEF (p 5 0.0003) and RVEF (p 5 0.002) were
predictive of the increase in LVEF.
CONCLUSIONS Patients with nonischemic cardiomyopathy who have higher left ventricular inotropic reserve
and normal RVEF derive higher increase in LVEF from beta-blocker therapy. (J Am Coll
Cardiol 2001;37:818–24) © 2001 by the American College of Cardiology
Recent clinical trials have demonstrated the beneficial ef-
fects of several beta-adrenergic receptor blockers on survival
in large groups of patients with chronic heart failure (CHF)
(1–4). Although concordant in their overall results, these
studies have several unexplained inconsistencies (1–7) and
the effect of beta-blockers on survival appears heteroge-
neous. Not all patients with heart failure benefit from
beta-blocker therapy, and there are no good means to
predict who will derive a benefit. With the expanding
medical regimen and cost of care, the ability to identify
patients with high likelihood of improvement is desirable.
The same clinical trials, and several smaller earlier studies,
have also demonstrated a consistent increase in the mean
left ventricular ejection fraction (LVEF) after beta-blocker
therapy (1–16). This sustained noninotrope-induced im-
provement of left ventricular systolic function appears to be
a marker for decreased risk of death and reduced morbidity
(16–18). Other than dose, no definite predictors of beta-
blocker-induced increase in LVEF have been identified
(16). The identification of patients who are most likely to
derive an increase in LVEF with beta-blocker therapy
might therefore allow for the identification of patients who
are highly likely to derive a survival benefit.
Ventricular systolic dysfunction is associated with de-
crease in the density of the b1 and sensitivity of the b2
adrenergic receptors that lead to heterogeneous decrease in
contractile response to adrenergic stimulation (19–22). This
variably diminished inotropic reserve appears to be an
independent predictor of survival (23–26). Although higher
inotropic reserve predicts better survival, it is associated with
higher relative risk of sudden cardiac death (26). It identifies
ventricles more responsive to adrenergic stimulation and
therefore likely more susceptible to the harmful effects of
chronic sympathetic activation (27). Because beta-blocker
therapy reduces the risk of sudden and progressive heart
failure death (1–4), higher inotropic reserve might identify
patients who are most likely to benefit from such therapy.
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The purpose of this study is to determine whether higher
left ventricular inotropic reserve, defined as the increase in
LVEF in response to intravenous dobutamine infusion
(DoDLVEF), predicts the increase in LVEF (DLVEF) after
long-term beta-blocker therapy in CHF patients with non-
ischemic dilated cardiomyopathy (NICM).
METHODS
Patients. The study subjects were 30 consecutive ambula-
tory patients with stable chronic heart failure and nonisch-
emic cardiomyopathy, LVEF # 0.35, who were started on
beta-blockers at the Yale Heart Failure Clinic. There were
20 men and 10 women. Mean age was 49 6 11 years (range
22 to 75 years), and mean duration of CHF was 3.2 6 2.9
years. Mean functional class (NYHA classification) was
2.6 6 0.5. All patients were in normal sinus rhythm except
for one with atrial fibrillation. Coronary artery disease was
excluded by coronary angiography. The etiology of cardio-
myopathy was either hypertensive or idiopathic. The study
was performed under an Institutional Review Board-
approved protocol, and informed written consent was ob-
tained. Patient characteristics are summarized in Table 1.
Radionuclide ventriculography. All study subjects under-
went gated equilibrium radionuclide angiocardiography at
rest and during the last 5 min of a 15-min peripheral
intravenous infusion of dobutamine (Dobutrex, Eli Lilly &
Co., Indianapolis, Indiana) at a dose of 10 mg/kg/min.
Right and left ventricular ejection fractions were measured
after modified in vivo red blood cell labeling (25–30 mCi
Technetium-99m pertechnetate) according to standardized
techniques (28). Data were acquired in electrocardiographic-
synchronized frame mode (16 frames/RR cycle) in 64 3 64
computer matrix. Global LVEF was computed from the left
anterior oblique image using validated and standardized
software (29). A varying left ventricular region of interest
and a cycle-dependent background region were used. The
computer software automatically determines left ventricular
edges and background, but also allows for operator interac-
tion as may be necessary in patients with intense radiotracer
accumulation adjacent to the left ventricle. Left ventricular
ejection fraction was determined from the fitted curve in the
usual manner: end-diastolic counts minus end-systolic
counts, divided by end-diastolic counts. Using this software
the lower limit of normal LVEF is 0.50. The reproducibility
of LVEF measurement using this software is excellent (30).
Right ventricular ejection fraction (RVEF) was computed
in 21 patients using the electrocardiogram (ECG)-gated
first pass technique (31). Using this method, the injection of
the patient’s Tc-99m-labeled red blood cells was used to
acquire ECG-gated right anterior oblique images of the
transit of radioactive bolus through the right ventricle. Data
acquisition was stopped when the bolus entered the pulmo-
nary artery. In this manner there was no overlap with other
cardiac structures. Two regions of interest were then drawn
manually over the end-diastolic and end-systolic contours of
the right ventricle. No background subtraction was applied.
Right ventricular ejection fraction was calculated from right
ventricular end-diastolic and end-systolic counts in the
usual manner. Using this method the lower limit of normal
RVEF is 0.40 (31). A qualitative assessment of RVEF was
performed in all 30 patients by visual inspection of the
morphology and contraction of the right ventricle on the
cine display in the anterior and left anterior oblique equi-
librium views. Using this visual approach, global right
ventricular function was categorized as either normal or
abnormal. Left ventricular end-diastolic volume (LVEDV)
was determined using the Massardo count ratio method
Abbreviations and Acronyms
CHF 5 chronic heart failure
DBP 5 diastolic blood pressure
DLVEF 5 change in left ventricular ejection fraction
after beta-blocker treatment
DoDLVEF 5 dobutamine-induced increase in left
ventricular ejection fraction
ECG 5 electrocardiogram
HR 5 heart rate
LVEDVI 5 left ventricular end-diastolic volume index
LVEF 5 left ventricular ejection fraction
NICM 5 nonischemic cardiomyopathy
RVEF 5 right ventricular ejection fraction
SBP 5 systolic blood pressure
Table 1. Patient Characteristics
Characteristics
Before
Beta-Blockers
After
Beta-Blockers
p
Value
Number 30 30
Age 49 6 11
Gender (M/F) 20/10
Duration of CHF (yr) 3.2 6 2.9
Functional class* 0.007
I/II 13 24
III/IV 17 6
Medications
ACEI/ARB 100% 97%
Furosemide 90% 77%
Metolazone 20% 10%
Aldactone 40% 33%
Digoxin 90% 77%
HR 85 6 13 74 6 9 0.0001
SBP 113 6 18 114 6 17 ns
DBP 72 6 9 71 6 10 ns
LVEF 0.21 6 0.07 0.34 6 0.13 0.0006
DoDLVEF 0.12 6 0.08
RVEF (n 5 21) 0.43 6 0.12 0.46 6 0.12 ns
RVEF abnormal (n 5 30) 37% 20% ns
Dose of beta-blocker
reached, mg
Carvedilol (n) 66 6 30 (22)
Bucindolol (n) 75 6 32 (7)
Metoprolol (n) 50 (1)
*NYHA classification.
ACEI 5 angiotensin-converting enzyme inhibitor; ARB 5 angiotensin receptor
blocker; CHF 5 chronic heart failure; DBP 5 diastolic blood pressure; DoDLVEF 5
dobutamine-induced increase in LVEF; HR 5 heart rate; LVEF 5 left ventricular
ejection fraction; RVEF 5 right ventricular ejection fraction; SBP 5 systolic blood
pressure.
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(32) and was indexed to the body surface area. Under this
method, normal patients have LVEDV 100–150 ml.
Beta-blocker therapy. All patients were on standard med-
ical therapy before initiation of beta-blocker therapy (Table
1). None were on intermittent or chronic intravenous
inotropic infusion therapy. Patients were started on one of
three beta-blockers: 22 on carvedilol, seven on bucindolol
and one on metoprolol succinate. The median period from
baseline ventriculographic study until start of beta-blocker
therapy was one month. The dose was increased as tolerated
every one to two weeks up to the target or maximally
tolerated dose. Target dose for carvedilol was 25 mg twice
daily for patients weighing #85 kg, otherwise 50 mg twice
daily; for bucindolol 50 mg twice daily for patients weighing
#75 kg, otherwise 100 mg twice daily; and for metoprolol
200 mg daily. Left ventricular ejection fraction was reas-
sessed at least three months after the initiation of beta-
blocker therapy.
Statistical analysis. Data were expressed as mean 6 stan-
dard deviation. The paired t test was used for comparison of
continuous variables within groups and the nonpaired t test
for comparison between groups. Fisher exact probability
test was used for comparison of noncontinuous variables.
Simple linear regression and correlation analysis were used
to examine the relation between the increase in LVEF
(DLVEF) and baseline clinical and ventriculographic vari-
ables. The Shapiro-Wilk statistic tested the null hypothesis
that the sample data were derived from a normally distrib-
uted population. Two-sided p value ,0.05 was considered
statistically significant.
Multivariate analysis was performed to determine which
of the following baseline clinical and ventriculographic
variables were associated with the increase in LVEF after
beta-blocker therapy: LVEF, RVEF, DoDLVEF, left ven-
tricular end-diastolic volume index (LVEDVI), systolic
blood pressure (SBP) at end of dobutamine infusion, dura-
tion of CHF, duration of treatment and dose. A stepwise
multiple regression procedure was used, with an entry
significance level of p , 0.10 and an exit significance level
of p . 0.20. All analyses were performed using PC-SAS
6.12 (SAS Institute Inc., Cary, North Carolina).
RESULTS
Beta-blocker dose and duration of therapy. The attained
daily dose of beta-blocker was 66 6 30 mg of carvedilol,
75 6 32 mg of bucindolol, and 50 mg of metoprolol. The
period from initiation of beta-blocker therapy until attain-
ment of final dose was 2 6 1 months (median 2 months).
Left ventricular ejection fraction was reassessed 7.4 6 5.9
months after maximal beta-blocker dose was reached (me-
dian 6.5 months).
Ventriculographic findings. Before beta-blocker therapy,
LVEF was 0.21 6 0.07 (range 0.08 to 0.35). Right
ventricular ejection fraction was abnormal in 11 patients
(37%). Quantitative RVEF, obtained in 21 patients, was
0.43 6 0.12. LVEDVI was 180 6 64 ml/m2. Before
dobutamine infusion, heart rate (HR) was 80 6 11 and SBP
was 123 6 17 mm Hg. At end of infusion HR was 106 6
18 and SBP 133 6 24 mm Hg. With dobutamine infusion,
LVEF increased to 0.33 6 0.13. Mean dobutamine-
induced increase of LVEF (DoDLVEF) was 0.12 6 0.08
(median 0.10, range 0.02 to 0.35)
After beta-blocker therapy LVEF increased to 0.34 6 0.13
(DLVEF 0.14 6 0.09, p 5 0.0006) (Table 1). There was
significant linear correlation between DoDLVEF and each of
RVEF (r 5 0.66, p 5 0.001), LVEF (r 5 0.52, p 5 0.003),
SBP on dobutamine (r 5 0.47, p 5 0.008) and LVEDVI (r 5
20.47, p 5 0.01). The linear correlation between DoDLVEF
and other baseline variables (duration of CHF, peak HR
and change in HR on dobutamine) was not significant.
Table 2 compares the clinical and ventriculographic
characteristics of patients with high versus low dobutamine-
induced increase in LVEF, and Table 3 compares the
characteristics of patients on the basis of the increase in
LVEF after beta-blocker therapy.
Predictors of LVEF improvement. The increase in LVEF
(DLVEF) after beta-blocker therapy was significantly cor-
related to baseline inotropic reserve, DoDLVEF (r 5 0.57,
p 5 0.001), RVEF (r 5 0.50, p 5 0.005), SBP at end of
dobutamine infusion (r 5 0.43, p 5 0.02) and dose of
beta-blocker (r 5 0.33, p 5 0.07) (Figs. 1 and 2). There was
no significant correlation between DLVEF and the rest of
baseline ventriculographic and clinical variables. In mul-
tivariate analysis only DoDLVEF (p 5 0.0003), and
RVEF (p 5 0.002) were significantly associated with the
increase in LVEF after beta-blocker therapy. The posi-
tive predictive value of DoDLVEF was 100% and its
negative predictive value was 67%. The positive and
negative predictive values of RVEF were 89% and 73%,
respectively (Table 4).
Table 2. Clinical and Ventriculographic Characteristics of
Patients with Low versus High Response to Dobutamine
DoDLVEF
< 0.10
DoDLVEF
> 0.10
p
Value
Number 15 15
Age (yr) 49 6 13 49 6 10
Gender (M/F) 8/7 12/3
Functional class* ns
II 5 8
III 10 7
Median duration of
CHF (yr)
3.5 1.1
LVEF 0.18 6 0.05 0.23 6 0.08 0.05
DoDLVEF 0.06 6 0.03 0.18 6 0.07 , 0.0001
RVEF (abnormal) 53% 20% ns
LVEDVI (ml/m2) 203 6 69 157 6 50 0.05
Median dose of
beta-blocker (mg)
50 100
DLVEF 0.08 6 0.08 0.20 6 0.06 , 0.0001
*NYHA classification.
LVEDVI 5 left ventricular end-diastolic volume index; DLVEF 5 change in left
ventricular ejection fraction. Other abbreviations as in Table 1.
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DISCUSSION
This study shows that left ventricular inotropic reserve and
right ventricular function are independent predictors of the
increase in LVEF after beta-blocker therapy in a well-
defined cohort with severe nonischemic left ventricular
systolic dysfunction. Specifically, patients with the highest
dobutamine-induced augmentation of LVEF and normal
RVEF derived the highest increase in LVEF after long-
term beta-blocker therapy. This relation was independent of
resting LVEF, dose of beta-blocker, duration of disease and
duration of treatment. These findings could help identify
patients with NICM who are most likely to derive signifi-
cant benefit from beta-blocker therapy. Patients who derive
the highest increase in LVEF are likely to be at lower risk
for progressive heart failure death, and because beta-blocker
therapy also reduces the risk of sudden cardiac death (1–4),
these patients also incur a lower risk of sudden death.
Although proven for large patient populations, the benefit
of beta-blockade has not yet been conclusively established
for all subgroups, and not all CHF patients benefit from it
(1–7). An increased sophistication in the identification of
patients who are most likely to derive a benefit should allow
for the extension of this potentially highly beneficial therapy
to a large segment of the CHF population.
Significance of higher inotropic reserve. Inotropic re-
serve, as measured in this study, is a reflection of the
contractile response to the stimulation of the myocardial
adrenergic signaling pathways. Although it is not a true
measure of myocardial contractile reserve, an entity that is
difficult to define, inotropic reserve provides a measure of
the responsiveness of the myocardial adrenergic signaling
pathways as well as that of the myocardial contractile
apparatus. Higher inotropic reserve identifies ventricles with
less downregulation of beta-adrenergic receptors. These
ventricles are probably more susceptible to the arrhythmo-
genic and myotoxic effects of chronic sympathetic activation
(27). Higher inotropic reserve is also a marker of the overall
health of the ventricle and is an independent predictor of
survival (23–26). These ventricles tend to have better left
and right ventricular function, smaller size and shorter
duration of disease (Table 2). These seem to be the
ventricles that are more likely to derive a significant and
sustained increase in LVEF from beta-blocker therapy
(Table 3). Although the positive predictive value of higher
inotropic reserve was perfect, its negative predictive value
was only 67%. Therefore, even patients with low inotropic
reserve might derive a significant increase in LVEF from
Figure 1. Change in left ventricular ejection fraction (LVEF) after beta-
blocker therapy versus baseline dobutamine-induced increase in LVEF.
Figure 2. Change in left ventricular ejection fraction (LVEF) after beta-
blocker therapy versus baseline right ventricular function. RVEF 5 right
ventricular ejection fraction.
Table 3. Clinical and Ventriculographic Characteristics of
Patients Based on the Increase in LVEF after
Beta-blocker Therapy
DLVEF
< 10
DLVEF
> 10
p
Value
Number 10 20
Age (yr) 49 6 12 48 6 11
Gender (M/F) 5/5 15/5
Functional class* ns
II 2 11
III 8 9
Median duration of
CHF (yr)
3.6 1
LVEF 0.17 6 0.05 0.23 6 0.07 0.02
DoDLVEF 0.05 6 0.04 0.15 6 0.07 , 0.0001
RVEF (abnormal) 80% 15% 0.002
LVEDVI (ml/m2) 211 6 76 165 6 52 0.06
Median dose of
beta-blocker (mg)
50 100
DLVEF 0.03 6 0.03 0.19 6 0.05 , 0.0001
*NYHA classification. Abbreviations as in Table 2.
Table 4. Predictive Values for Beta-Blocker-Induced Increase
in LVEF
Positive
Predictive Value
Negative
Predictive Value
DoDLVEF 100% 67%
RVEF 89% 73%
Abbreviations as in Figure 2.
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beta-blocker therapy. Of course, these patients and others
might derive a clinical benefit from beta-blockade in the
absence of increase in LVEF.
Increase in LVEF and survival. An increase in the mean
LVEF was the most consistent effect of beta-blocker ther-
apy in multiple studies (1–16). The exact mechanism of this
increase remains uncertain (17). Despite the large database
of heart failure patients treated with beta-blockers, other
than dose there are no definitively established predictors of
the increase in LVEF. Furthermore, there are no well-
established clinical markers of higher likelihood of survival
after beta-blocker therapy. Given that the improvement of
survival has been adopted as the most important therapeutic
goal, such markers would be quite useful in several ways.
They would allow for the identification of patients most
likely to benefit from treatment. They would also provide
surrogate endpoints in the evaluation of newer therapeutic
agents. Recent data suggest that the sustained long-term
increase in LVEF after beta-blocker therapy might predict
lower likelihood of death, at least from progressive heart
failure, and better clinical outcomes (16–18). Although
patients with higher LVEF have lower risk of all-cause
mortality (33), they have higher relative risk of sudden
cardiac death (34–36). Higher inotropic reserve could be a
consequence of more responsive adrenergic signaling path-
ways. These pathways are involved in the mediation of
ventricular tachyarrhythmia (37), a common cause of sud-
den death in nonischemic cardiomyopathy (38–41). Higher
inotropic reserve might therefore identify patients who are
at highest relative risk for sudden arrhythmic death and
those of higher likelihood to derive an increase in LVEF
after beta-blocker therapy.
RVEF and increase in LVEF. In this study normal right
ventricular function was also associated with increase in
LVEF after beta-blocker therapy. Normal RVEF is another
marker of healthier hearts and an independent predictor of
better survival (42,43). Ventricles with higher DoDLVEF
tend to have higher RVEF (26). Although this could in part
be due to the hemodynamic coupling of right and left
ventricular function, it is more likely a reflection of the
extent of ventricular contractile impairment. Because RVEF
is easy to assess, it might serve as a practical means to
identify candidates for beta-blocker therapy. It should not,
however, be the sole criterion, as many patients with
impaired right ventricular function also derive benefit from
beta-blockade in the form of increase in LVEF and RVEF
and better survival (44). In this study, a normal RVEF had
a lower positive predictive value than did inotropic reserve,
but its negative predictive value was higher.
Patients with ischemic cardiomyopathy. This study
aimed to examine the predictive value of adrenergic ino-
tropic reserve on the increase in LVEF after beta-blocker
therapy. The exclusion of patients with coronary artery
disease eliminated the complicating effects of myocardial
ischemia and prior infarction on the evaluation of adrenergic
inotropic reserve. The presence and extent of coronary
artery disease, ischemic burden and old myocardial infarc-
tion all make the assessment of inotropic reserve imprecise.
The viable dysfunctional myocardium has the same down-
regulation of adrenergic receptors and diminished inotropic
reserve. The response of the entire ventricle to adrenergic
agents, however, depends on the extent of infarcted myo-
cardium and the presence of hemodynamically important
coronary artery disease. If there is extensive ischemic bur-
den, adrenergic stimulation might increase oxygen demand
and worsen ischemia. This might blunt the contractile
response or even diminish the ejection fraction, rendering
the assessment of inotropic reserve imprecise. The results of
this study therefore cannot be extended to patients with
ischemic cardiomyopathy.
Study limitations. This observational study in a small,
albeit well-defined, cohort of young nonischemic cardiomy-
opathy patients was designed to test a specific hypothesis. It
should not serve as a means for selecting patients for
beta-blocker therapy. Now that the benefit of beta-blockade
has been established in large and heterogeneous populations
of heart failure, further studies are needed to define the
patients who are most likely to benefit from this therapy.
This study is a step in that direction. It employed the three
beta-blockers most extensively studied in heart failure, and
which were all shown to increase LVEF in multiple previous
studies. Because of the small number of patients involved in
this study, it is not certain whether the findings apply to all
three beta-blockers. Also, because of the small number of
patients, it is not possible to adjust for any confounders.
Although qualitative right ventricular function assessment
was performed in all patients and used in the analysis,
quantitative RVEF was not obtained in 30% of the subjects.
Peripheral dobutamine infusion has multiple effects on
the heart. In addition to increasing force of contraction, it
can increase HR and change pulmonary and systemic
vascular resistance. The sum effect of these hemodynamic
changes could contribute to the change in LVEF with
dobutamine infusion. In this study, there was no correlation
between the dobutamine-induced increase in LVEF and
peak HR, change in HR or change in SBP at peak
dobutamine infusion. Furthermore, a weak positive corre-
lation existed between DoDLVEF and SBP at peak dobut-
amine infusion. Although intracoronary infusion of dobut-
amine minimizes peripheral effects on cardiac loading and is
therefore a more precise method for the assessment of
inotropic reserve (22,25), intravenous dobutamine infusion
is less invasive, safer and clinically practicable. The dose of
dobutamine used in this study was chosen based on previous
experience (26). It was intended to maximize inotropic
response while minimizing chronotropic response, risk of
dysrhythmia and the peripheral effects of dobutamine.
Infusion duration of 10 min prior to repeat imaging allows
for the attainment of steady state.
Conclusions. This study showed that NICM patients with
normal right ventricular function and higher left ventricular
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inotropic reserve are most likely to derive an increase in
LVEF after long-term treatment with beta-blockers. Fur-
ther studies are needed to determine whether this finding
would identify patients more likely to derive survival benefit
from beta-blockade.
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